Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK). In such way LND could impair energy-requiring processes, as recovery from potentially lethal damage, induced by radiation treatment and by some cytotoxic drugs. Its therapeutic use is listed as antineoplastics. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Diclondazolic Acid and Doridamina. Its PubChem CID is 39562.
Lonidamine
| CAS No | 50264-69-2 |
|---|---|
| Molecular Formula | C15H10Cl2N2O2 |
| Molecular Weight | 321.20 g/mol |
| Synonyms | 1-[(2,4-dichlorophenyl)methyl]indazole-3-carboxylic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Lonidamine (LND) is a drug that interferes with energy metabolism of cancer cells, principally inhibiting aerobic glycolytic activity, by its effect on mitochondrially-bound hexokinase (HK).
The listed CAS number is 50264-69-2.
The listed molecular formula is C15H10Cl2N2O2.
The listed molecular weight is 321.20 g/mol.
1-[(2,4-dichlorophenyl)methyl]indazole-3-carboxylic acid.
The source lists Diclondazolic Acid and Doridamina.